Sam – Page 205 – biolegacy

Suitors Weigh Bids for Sanofi's $3B European Generics Biz

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

The portfolio consists of acute, chronic and oncology products. Source: BioSpace

PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

The company believes the Translarna data is compelling and pointed to the success the drug is having in Europe. Source: BioSpace

The 7 Best Life Science Companies to Work for in 2018

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

Here's a look at the seven best life science companies to work for in 2018. Source: BioSpace

What You Need to Know About Hyalex Orthopaedics

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage. Source: BioSpace

4 Major Biopharmas: What Went Down at JPM 2018

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference. Source: BioSpace

Teva Board Members Take 50% Pay Cut

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

Teva has made a target of cutting costs by $3B by the end of 2019. Source: BioSpace

EMA Publishes New Guidance on Rheumatoid Arthritis Drug Trials

Post author:Sam
Post published:January 10, 2018
Post category:Drug Industry Daily

The European Medicines Agency updated guidance on clinical investigations of rheumatoid arthritis drugs to add new endpoints and distinguish between patient subgroups in trials. Source: Drug Industry Daily

South Dakota Tribes Sue Opioid Drugmakers for RICO Violations

Post author:Sam
Post published:January 10, 2018
Post category:Drug Industry Daily

Three South Dakota tribes sued two dozen drugmakers including Allergan, Teva and Purdue alleging the companies violated the Racketeer Influenced and Corrupt Organizations (RICO) act and engaged in fraud and…

CDER Celebrates Novel Approvals and Highlights Other Firsts in 2017

Post author:Sam
Post published:January 10, 2018
Post category:Drug Industry Daily

CDER achieved numerous firsts in its past year of drug approvals, covering treatments for several rare diseases, cancer therapies and antibiotics. Source: Drug Industry Daily

E&C Committee Reviews 340B Drug Pricing Program, Offers Recommendations

Post author:Sam
Post published:January 10, 2018
Post category:Drug Industry Daily

The House Energy and Commerce Committee released a review of the 340B drug discount pricing program, identifying weaknesses in oversight and administration, among other issues, and offering recommendations to resolve…